CONMED Corporation
US ˙ NYSE ˙ US2074101013

SecurityCNMD / CONMED Corporation
InstitutionEarnest Partners Llc
Latest Disclosed Ownership2,784,300 shares
Ownership 9.00%
Earnest Partners Llc ownership in CNMD / CONMED Corporation

2024-11-13 - Earnest Partners Llc has filed an SC 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 2,784,300 shares of CONMED Corporation (US:CNMD). This represents 9.0 percent ownership of the company. In their previous filing dated 2024-02-12 , Earnest Partners Llc had reported owning 2,345,697 shares, indicating an increase of 18.70 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date
Effective
Date
Form Prev
Shares
Latest
Shares
ΔShares
(Percent)
Ownership
(Percent)
ΔOwnership
(Percent)
2024-11-13 2024-11-13 13G/A 2,345,697 2,784,300 18.70 9.00 18.42
2024-02-12 2024-02-12 13G/A 2,402,352 2,345,697 -2.36 7.60 -3.80
2023-02-13 2023-02-13 13G/A 1,661,792 2,402,352 44.56 7.90 41.07
2022-07-11 2022-07-11 13G/A 1,477,262 1,661,792 12.49 5.60 12.00
2022-03-10 2022-03-10 13G/A 1,519,323 1,477,262 -2.77 5.00 -3.85
2022-02-14 2022-02-14 13G/A 1,575,336 1,519,323 -3.56 5.20 -5.45
2021-02-16 2021-02-16 13G 1,575,336 5.50

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F CONMED COM 207410101 2,569,653 -93,300 -3.50 90,863 -15.96 0.3746
2026-02-12 2025-12-31 13F CONMED COM 207410101 2,662,953 -135,750 -4.85 108,116 -17.86 0.4633
2025-11-14 2025-09-30 13F CONMED COM 207410101 2,798,703 -31,212 -1.10 131,623 -10.69 0.5710
2025-08-15 2025-06-30 13F CONMED COM 207410101 2,829,915 30,216 1.08 147,382 -12.83 0.6644
2025-05-14 2025-03-31 13F CONMED COM 207410101 2,799,699 -10,477 -0.37 169,074 -12.09 0.8096
2025-02-14 2024-12-31 13F CONMED COM 207410101 2,810,176 25,876 0.93 192,328 -3.95 0.8596
2024-11-14 2024-09-30 13F CONMED COM 207410101 2,784,300 -34,306 -1.22 200,247 2.49 0.8719
2024-08-14 2024-06-30 13F CONMED COM 207410101 2,818,606 447,498 18.87 195,386 2.90 0.9135
2024-05-15 2024-03-31 13F CONMED COM 207410101 2,371,108 25,411 1.08 189,878 -26.08 0.8693
2024-02-14 2023-12-31 13F CONMED COM 207410101 2,345,697 80,605 3.56 256,877 12.45 1.2826
2023-11-14 2023-09-30 13F CONMED COM 207410101 2,265,092 44,076 1.98 228,435 -24.31 1.3175
2023-08-07 2023-06-30 13F CONMED COM 207410101 2,221,016 -494,873 -18.22 301,814 7.00 1.6870
2023-05-15 2023-03-31 13F CONMED COM 207410101 2,715,889 313,537 13.05 282,072 32.46 1.6314
2023-02-14 2022-12-31 13F CONMED COM 207410101 2,402,352 335,974 16.26 212,944 28.54 1.3051
2022-11-14 2022-09-30 13F CONMED COM 207410101 2,066,378 404,586 24.35 165,662 4.10 1.1128
2022-08-12 2022-06-30 13F CONMED COM 207410101 1,661,792 187,134 12.69 159,133 -27.36 1.0600
2022-05-16 2022-03-31 13F CONMED COM 207410101 1,474,658 -44,665 -2.94 219,060 1.71 1.2974
2022-02-07 2021-12-31 13F CONMED COM 207410101 1,519,323 -83,807 -5.23 215,379 2.69 1.2423
2021-11-15 2021-09-30 13F CONMED COM 207410101 1,603,130 -25,718 -1.58 209,737 -6.31 1.2819
2021-08-16 2021-06-30 13F CONMED COM 207410101 1,628,848 -7,824 -0.48 223,853 4.73 1.3153
2021-05-17 2021-03-31 13F CONMED COM 207410101 1,636,672 61,336 3.89 213,733 21.14 1.2768
2021-02-16 2020-12-31 13F CONMED COM 207410101 1,575,336 459,191 41.14 176,438 100.94 1.2189
2020-11-16 2020-09-30 13F CONMED COM 207410101 1,116,145 1,116,145 87,807 0.7575
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.